Extended Data Fig. 1: Kinetics of infection and frequencies of antigen-specific CD8 T cells during hepatotropic adenoviral infection.
From: A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection
a,b, In vivo bioluminescence imaging kinetic after hepatotropic infection and quantification (two-way ANOVA with Tukey’s multiple comparisons; d0: resolved vs. chronic Padj=0.9295, resolved vs. uninfected Padj=0.0959, chronic vs. uninfected Padj=0.1498; d1: resolved vs. chronic Padj=0.9902, resolved vs. uninfected Padj=0.0209, chronic vs. uninfected Padj=0.1021; d3: resolved vs. chronic Padj=0.2179, resolved vs. uninfected Padj=0.1025, chronic vs. uninfected Padj=0.1269; d5: resolved vs. chronic Padj=0.1413, resolved vs. uninfected Padj=0.1270, chronic vs. uninfected Padj=0.0168; d7: resolved vs. chronic: Padj=0.8271, resolved vs. uninfected Padj=0.5733, chronic vs. uninfected Padj=0.1293; d17: resolved vs. chronic Padj=0.3965, resolved vs. uninfected Padj=0.6564, chronic vs. uninfected Padj=0.3961; d46: resolved vs. chronic Padj=0.0218, resolved vs. uninfected Padj=0.0766, chronic vs. uninfected Padj=0.0219; d98: resolved vs. chronic Padj=0.0087, resolved vs. uninfected Padj=0.8296, chronic vs. uninfected Padj=0.0087; n = 5). c, Quantification of adenoviral copies in liver tissue (two-way ANOVA with Sidak’s multiple comparison, resolved vs. chronic Padj<0.0001 for all timepoints, n = 4). d,e, Liver immunohistochemistry detecting GFP-expressing virus-infected hepatocytes in brown (scale bar 50 µm) and quantification (two-way ANOVA with Tukey’s multiple comparisons for Padj, n = 3). f, Time kinetics of sALT (two-way ANOVA with Tukey’s multiple comparison, d0: uninfected vs. resolved Padj=0.0560, uninfected vs. chronic Padj=0.1210, resolved vs. chronic Padj=0.9971; d5: uninfected vs. resolved Padj=0.5088, uninfected vs. chronic Padj=0.0265, resolved vs. chronic Padj=0.6827: d7: uninfected vs. resolved Padj=0.0981, uninfected vs. chronic Padj=0.3799, resolved vs. chronic Padj=0.0163; d9: uninfected vs. resolved Padj=0.3044, uninfected vs. chronic Padj=0.1871, resolved vs. chronic Padj=0.1963; d12: uninfected vs. resolved Padj=0.0788, uninfected vs. chronic Padj=0.0442, resolved vs. chronic Padj=0.1289; d33: uninfected vs. resolved Padj=0.2294, uninfected vs. chronic Padj=0.1477, resolved vs. chronic Padj=0.0481; d46: uninfected vs. resolved Padj=0.9976, uninfected vs. chronic Padj=0.0102, resolved vs. chronic Padj=0.0809; d98: uninfected vs. resolved Padj=0.9274, uninfected vs. chronic Padj=0.2301, resolved vs. chronic Padj=0.1714; n = 5). g, Gating strategy for antigen-specific CD45.1+ T cells at d45 p.i. after adoptive transfer of 100 naive CD8 T cells on d-1 (n = 4). h,i, IFNγ and TNF expression by liver CD45.1+CD8 T cells at d45 p.i. after ex vivo re-stimulation with OVA257-264 -peptide and quantification (two-way ANOVA with Sidak’s and Tukey’s multiple comparison, n = 4). j,k, PD-1, TIGIT, TIM-3, LAG3 and TOX expression by liver and spleen CD45.1+CD8 T cells at d45 p.i. and quantification (one-way ANOVA with Tukey’s multiple comparison, n ≥ 4) One out of ≥ two independent experiments shown; LLOD = lower limit of detection; not significant (n.s.) p≥0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, errors shown as s.d.; FMO = fluorescence minus one, MFI = geometric mean fluorescence intensity, p.i. = post infection.
